The Malaysian Government is heavily subsidizing public healthcare expenditure in order to provide access to health care for all citizens. In 2017, total healthcare expenditure in the country was approximately 9.4% of the annual budget. In order to overcome the increasing cost of health care, the government has implemented a National Generic Medicine Policy in 2006 to promote healthier competition in medicine pricing and to make medicines more affordable to the general public. After 10 years of policy implementation, authors from the Ministry of Health Malaysia assess patients' beliefs about generics.
- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
General
- Crecimiento de medicamentos genéricos en Brasil y Venezuela
- EMA launches European shortages monitoring platform to tackle persistent medicine shortages
- Penetración de los medicamentos genéricos en México y Brasil
- FDA releases one-year progress report for the Generic Drug Cluster
-
Biosimilares
Novedades
- FDA approves filgrastim biosimilar Filkri
- EC approves golimumab biosimilar Gotenfia and ranibizumab biosimilar Ranluspec
- EMA recommends approval for teriparatide biosimilar Zandoriah
- FDA approves third interchangeable ranibizumab biosimilar Nufymco
Investigación
- Un estudio de la OCDE no encuentra una relación directa entre las normas de publicidad y la adopción de biosimilares
- Alcanzar los objetivos ASG en el desarrollo farmacéutico
- What is the future for the US biosimilar interchangeability designation
- Estudios de eficacia clínica en biosimilares: ¿siguen siendo necesarios?
General
- Biosimilars approved in Europe
- La SBR publica un posicionamiento sobre la intercambiabilidad segura entre biológicos originales y biosimilares
- Biosimilars approved in the US
- Samsung Bioepis wins Pyzchiva case; Regeneron patent rulings threaten foreign biosimilars
- MORE EDITORIAL SECTIONS
- Search




Post your comment